Loading
A phase 1/2 trial of TC011 in diffuse large b-cell lymphoma and follicular lymphoma, run by TICAROS Co., Ltd., now recruiting.
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients is a phase 1/2 interventional study registered as NCT07473167 by TICAROS Co., Ltd., with 98 participants planned, started 2023-08-03 and due to reach its primary completion in 2028-02-11. Interventions recorded: TC011. Conditions listed: Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBL). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/